Short drug course aims to shrink tumors before cancer surgery
NCT ID NCT04169074
Summary
This study tested if giving the drug abemaciclib for 10-21 days before surgery could shrink tumors in patients with HPV-negative head and neck cancer. The goal was to see if the drug reduced tumor size and changed the immune environment around the cancer. The trial was small and ended early, enrolling only 7 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
George Washington Cancer Center
Washington D.C., District of Columbia, 20037, United States
-
University of Arizona
Tucson, Arizona, 85719, United States
Conditions
Explore the condition pages connected to this study.